Related Experiment Video

Updated: Mar 26, 2026

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model
07:03

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model

Published on: March 18, 2019

7.9K

Mending a Faltering Heart

Mo Li1, Juan Carlos Izpisua Belmonte2

  • 1From the Gene Expression Laboratory, the Salk Institute for Biological Studies, La Jolla, CA (M.L., J.C.I.B.); and Universidad Católica San Antonio de Murcia (UCAM) Campus de los Jerónimos, Murcia, Spain (M.L.).

Circulation Research
|February 4, 2016
PubMed

Insights

Ischemic heart disease is a leading cause of death. Research is exploring cardiac regeneration mechanisms and stem cell therapies to repair heart muscle damage and improve outcomes.

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Cardiac Biology

Background:

  • Ischemic heart disease is the leading cause of mortality worldwide.
  • The human heart has limited capacity to regenerate damaged cardiac muscle.
  • Understanding heart homeostasis and regeneration is crucial for developing effective therapies.

Purpose of the Study:

  • To review recent advancements in understanding heart growth mechanisms during homeostasis and injury.
  • To explore the potential of stem cell biology and cellular reprogramming for cardiac regeneration.
  • To discuss novel strategies for treating heart disease.

Main Methods:

  • Analysis of observational studies in human populations.
  • Review of experimental research in animal models of cardiac regeneration.
  • Synthesis of current knowledge on stem cell biology and cellular reprogramming.

Main Results:

  • Significant progress has been made in elucidating the mechanisms of cardiac growth and repair.
  • Stem cell-based approaches and cellular reprogramming show promise for regenerating cardiac tissue.
  • New therapeutic strategies are emerging from these research advancements.

Conclusions:

  • Continued research into cardiac regeneration mechanisms is vital.
  • Stem cell biology and reprogramming offer innovative avenues for heart disease treatment.
  • Translating these findings into clinical practice could significantly improve patient outcomes.

Keywords:
cellular reprogramminginduced pluripotent stem cellsmyocardial infarctionmyocardial ischemiamyocytes, cardiac

More Related Videos

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K
Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
743
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
621
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
537
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
512
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.5K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
671